Review
Cell Biology
Vijay Kumar, Caitlin Bauer, John H. Stewart
Summary: Myeloid immune cells (MICs) are powerful innate immune responders that recognize altered cellular homeostasis. cGAS/STING signaling plays a critical role in detecting cytosolic dsDNA and activating immune responses. This article explores tumor-supportive changes in the tumor immune microenvironment and discusses the potential of targeting MIC-specific cGAS/STING signaling for tumor immunotherapy.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Review
Biochemistry & Molecular Biology
Natalia Di Ianni, Silvia Musio, Serena Pellegatta
Summary: Glioblastoma metabolism is flexible and adaptable to adverse conditions, with altered lipid metabolism also playing a role in tumor progression. Immunosuppressive microenvironment of GBM involves MDSCs as allies of tumor cells, and there is increasing evidence of interconnection between GBM and MDSC metabolic pathways. Understanding the metabolic programs of GBM and MDSCs is important for improving treatment modalities, including immunotherapeutic strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Liang Mao, Yao Xiao, Qi-Chao Yang, Shao-Chen Yang, Lei-Lei Yang, Zhi-Jun Sun
Summary: This study found that CD155 and PD-L1 are highly co-expressed on MDSCs in HNSCC patients, and the combined blockade of TIGIT/CD155 and PD-1/PD-L1 signaling significantly inhibited tumor growth in mouse models, enhanced the percentage of effector T cells, and induced immune memory effects.
Review
Immunology
Adeleye O. Adeshakin, Funmilayo O. Adeshakin, Dehong Yan, Xiaochun Wan
Summary: Immunotherapy is a promising approach to improve cancer treatment by addressing the immunosuppressive tumor microenvironment. The accumulation of immunosuppressive cells in the tumor microenvironment limits the effectiveness of this treatment. Recent studies have shown that inhibiting histone deacetylase expression on myeloid cells can reduce their immunosuppressive effect, sensitizing tumors to immune checkpoint inhibitors.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Tianmiao Ma, Bernhard W. Renz, Matthias Ilmer, Dominik Koch, Yuhui Yang, Jens Werner, Alexandr V. Bazhin
Summary: Myeloid-derived suppressor cells (MDSCs) play a crucial role in the tumor microenvironment (TME) and have been linked to poor prognosis and drug resistance in cancer. Further research is needed to fully understand the definition and phenotypes of MDSCs in humans.
Article
Immunology
Lisha Zhou, Xiongzhi Lin, Luyi Zhang, Siyuan Chen, Jiahao Chen, Zhukun Zhou, Ajun Tang, Jiachao Ruan, Xiaojun Wang, Baofu Chen
Summary: The neddylation pathway has been shown to play a significant role in regulating MDSC infiltration in lung adenocarcinomas (LUADs). Inhibition of this pathway can suppress the infiltration of MDSCs and impede lung cancer growth by inhibiting the expression of mCXCL5. The neddylation-NF-κB-mCXCL5 axis is involved in the recruitment of MDSCs to tumor sites, highlighting the neddylation pathway as a potential therapeutic target for LUAD patients, especially those undergoing anti-MDSC therapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Panpan Liu, Cong Peng, Xiang Chen, Lisha Wu, Mingzhu Yin, Jie Li, Qunshi Qin, Yehong Kuang, Wu Zhu
Summary: The study found that increased numbers of myeloid-derived suppressor cells (MDSCs) are involved in the development of psoriasis. Acitretin, a treatment for psoriasis, was shown to reduce the number of MDSCs and promote their differentiation into macrophages and dendritic cells. This effect was mediated by acitretin's regulation of glutathione synthesis and activation of extracellular signal-regulated kinase 1/2.
FRONTIERS IN MEDICINE
(2021)
Article
Oncology
Veronica Huber, Lorenza Di Guardo, Luca Lalli, Daniele Giardiello, Agata Cova, Paola Squarcina, Paola Frati, Anna Maria Di Giacomo, Lorenzo Pilla, Marcella Tazzari, Chiara Camisaschi, Flavio Arienti, Chiara Castelli, Monica Rodolfo, Valeria Beretta, Massimo Di Nicola, Michele Maio, Michele Del Vecchio, Filippo de Braud, Luigi Mariani, Licia Rivoltini
Summary: A multistep downsizing process identified a myeloid index score (MIS) composed of four cell subsets that stratified melanoma patients based on prognosis. The MIS serves as a simple blood biomarker in real-life oncology, aiding in tailoring therapeutic choices.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Ching-Chuan Hsieh, Cheng-Chih Chang, Yung-Chien Hsu, Chun-Liang Lin
Summary: In the development of diabetic kidney disease, the dysregulation of glomerular cell types is crucial, and MDSCs exhibit anti-inflammatory activities that help improve renal fibrosis in diabetic mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Alejandro Olivares-Hernandez, Luis Figuero-Perez, Eduardo Teran-Brage, Alvaro Lopez-Gutierrez, Alvaro Tamayo Velasco, Rogelio Gonzalez Sarmiento, Juan Jesus Cruz-Hernandez, Jose Pablo Miramontes-Gonzalez
Summary: Myeloid-derived suppressor cells (MDSCs) are immature myeloid lineage cells that have been associated with tumor processes, including resistance to immunotherapy. Current research suggests that MDSCs, in combination with immune checkpoint inhibitors (ICIs), may be used to treat various hematological neoplasms.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Zhaonian Hao, Ruyuan Li, Yuanyuan Wang, Shuangying Li, Zhenya Hong, Zhiqiang Han
Summary: MDSC play vital roles in cancer microenvironment, influencing the responses to immunotherapies and prognosis of cancer patients. Therefore, proposing MDSC-inhibiting strategies becomes crucial in the field of cancer immunotherapies.
BIOMARKER RESEARCH
(2021)
Review
Oncology
Hongchao Tang, Hao Li, Zhijun Sun
Summary: Immunotherapy is a promising breakthrough in cancer treatment, with immune checkpoint blockade showing positive clinical responses in different cancer types. However, the clinical efficacy of ICB is limited in some patients due to the immunosuppressive tumor microenvironment and the role of MDSCs. A combined treatment strategy using MDSC inhibitors and ICB is being proposed to enhance the antitumor efficacy.
CANCER BIOLOGY & MEDICINE
(2021)
Article
Cell Biology
Filippos Koinis, Anastasia Xagara, Evangelia Chantzara, Vassiliki Leontopoulou, Chrissovalantis Aidarinis, Athanasios Kotsakis
Summary: This article reviews the research progress on mechanisms involved in the response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have been identified as a major mediator of immunosuppression in the tumor microenvironment and strategies to enhance anti-tumor immune response via MDSC targeting are being explored. The article summarizes the current methodologies for phenotypic and metabolic characterization of MDSCs in PCa and discusses their potential impact on clinical outcomes. Additionally, emerging strategies for therapeutically targeting MDSCs are briefly discussed.
Article
Cell Biology
Karolina Okla
Summary: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that accumulate in the tumor microenvironment and play a significant role in cancer. The high abundance of MDSCs often leads to immunosuppression, tumor growth, treatment failure, and poor prognosis. Ovarian cancer, ranking fifth in cancer deaths among women, lacks effective clinical strategies for treatment. Despite the negative role of human MDSCs in ovarian cancer, this topic remains understudied. This article summarizes the research on MDSCs and explains why focusing on these cells could be a promising approach in treating ovarian cancer patients.
Article
Biochemistry & Molecular Biology
Zibing Wang, Yuqing Liu, Ling Peng, Brian Till, Yuwei Liao, Shumin Yuan, Xiang Yan, Lin Chen, Qiang Fu, Zhihai Qin
Summary: The role of B cells in the anti-tumor immune response is controversial. An increase in the number of B cells in the peripheral blood of some tumor patients has been associated with poor immunotherapy efficacy. This study suggests that CD11b(+) myeloid cells promote B cell proliferation, activation, and survival, and targeting B cells may increase the efficacy of immunotherapy in tumor-bearing hosts.
